stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) EV/FCF
As of 6 November 2026, Xeris Biopharma Holdings, Inc. (XERS) trades at a EV/FCF of 39.4×. Over the past ten years it has ranged from −89.1× (September 2025) to 176× (November 2025); the current reading is higher than 95% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 49.4× | — |
| FY2024 | −17.4× | — |
| FY2023 | −8.8× | — |
| FY2022 | −2.1× | — |
| FY2021 | −2.3× | — |
| FY2020 | −2.1× | — |
| FY2019 | −1.6× | — |
| FY2018 | −2.1× | — |
| FY2017 | −0.3× | — |
| FY2016 | −0.3× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 25.5× | (5.43%) |
| Jun 2026 | 26.9× | 15.27% |
| Mar 2026 | 23.4× | (52.72%) |
| Dec 2025 | 49.4× | (66.50%) |
| 33 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMLX Amylyx Pharmaceuticals, Inc. compare | −23.0× |
| ALVO Alvotech compare | −12.2× |
| RGC Regencell Bioscience Holdings Limited compare | 0.9× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 6.6× |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 7.5× |
| TRLV Trulieve Cannabis Corp. compare | 12.4× |
| PBH Prestige Consumer Healthcare Inc. compare | 19.1× |
| PRGO Perrigo Company plc compare | 28.7× |
| XERS Xeris Biopharma Holdings, Inc. | 39.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on XERS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement